CDKN2A

Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics

Retrieved on: 
星期三, 四月 3, 2024
Sarcoma, Diagnosis, KT, Oncogene, SAN, Neoplasm, Research, Cancer, Doctor of Philosophy, CDKN2A, Workflow, Karyotype, FISH, Genomics, Chromothripsis, SVS, Prognosis, Aberration, OGM, Medical imaging

Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.

Key Points: 
  • Sarcomas represent over 100 histological subtypes and are highly heterogenous in their genetic landscape and prognosis.
  • The detection of SVs and CNVs remains challenging and typically requires multiple traditional cytogenetic techniques.
  • In this study, researchers demonstrated OGM’s ability to detect aberrations as small as 500 bp, which is approximately 10,000-fold higher resolution than that of KT.
  • As shown in this study, OGM can provide better characterization of the genomic complexity of sarcoma samples when compared to traditional cytogenetic techniques, due to the workflow’s high resolution and ​comprehensive, genome-wide analysis.

Ryvu Therapeutics to Present Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meeting

Retrieved on: 
星期三, 三月 6, 2024
WBC, WRN, Lung cancer, RNA, Malignancy, Microsatellite instability, Proteome, Intellectual property, MMR, MPN, Glioblastoma, Neoplasm, Splenomegaly, DMPK, Phosphorylation, HDAC, STAT5, RNA-Seq, WES, Standard of care, Therapy, RecQ helicase, Phenotype, Ruxolitinib, DNA, DNA repair, Pancreatic serous cystadenoma, CDKN2A, Cancer, CRC, PIM, Arginine, MTA, Abstract, PDC, MTAP, Colorectal cancer, CRISPR, PV, MF, MSI-H, Cell, JAK, DNA mismatch repair, Medicine, Patient, Gene, PRMT5, Haematopoiesis, Mesothelioma, Pharmaceutical industry

Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.

Key Points: 
  • Ryvu's partner Menarini to present data on MEN1703 (SEL24), demonstrating promising anti-tumor activity in preclinical models of myelofibrosis both as a single agent and combined with ruxolitinib.
  • "We are excited to present our latest preclinical data at the AACR Annual Meeting, showcasing our significant progress in advancing novel small molecule therapies for oncology.
  • This year, we will present data from our most advanced preclinical project on MTA-cooperative PRMT5 inhibitors, the lead program within Ryvu's synthetic lethality pipeline.
  • Ryvu has developed potentially best-in-class MTA-cooperative PRMT5 inhibitors showing favorable drug-like properties and effective PRMT5 inhibition dependent on MTA binding.

Rain Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

Retrieved on: 
星期四, 三月 9, 2023
RAIN, Pharmacokinetics, Neoplasm, Patient, Clinical trial, CDKN2A, Webcast, Cancer, G&A, Observation, Liposarcoma, MANTRA, Journal, Exercise, Investment, DD, Corporation, Doctor of Philosophy, MD, Therapy, American Journal of Clinical Oncology, Safety, Pharmaceutical industry, Medical imaging, Cryptocurrency

As of December 31, 2022, Rain had $130.5 million in cash, cash equivalents and short-term investments.

Key Points: 
  • As of December 31, 2022, Rain had $130.5 million in cash, cash equivalents and short-term investments.
  • Rain will continue to assess its cash runway and provide further guidance, if appropriate, after the release of MANTRA topline results in the second quarter of this year.
  • As of December 31, 2022, Rain had approximately 36.3 million shares of common stock outstanding.
  • The management of Rain Oncology will host a conference call and webcast for the investment community today, March 9, 2023 at 2:00 pm PT (5:00 pm ET).

Rain Therapeutics Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

Retrieved on: 
星期四, 十一月 10, 2022
GLOBE, Private Securities Litigation Reform Act, IO, PRS, Health, Investment, Doctor of Philosophy, U.S. Securities and Exchange Commission, Liposarcoma, Nasdaq, CDKN2A, Food, Webcast, Daiichi Sankyo, Research, RAD52, G&A, COVID-19, RECIST, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Genetics, R, Safety, International, LPS, Histology, RAIN, Coronavirus Scientific Advisory Board (Turkey), Clinical trial, Biotechnology, Patient, Corporation, Security (finance), Progression-free survival, Bachelor of Medicine, Bachelor of Surgery, MD, Biliary tract, FDA, MDM2, Pharmaceutical industry, Medical imaging, Management

We plan to initiate the MANTRA-4 trial next quarter and remain very excited about this second tumor agnostic basket strategy.

Key Points: 
  • We plan to initiate the MANTRA-4 trial next quarter and remain very excited about this second tumor agnostic basket strategy.
  • As of September 30, 2022, Rain had $90.7 million in cash, cash equivalents and short-term investments as compared to $140.2 million at December 31, 2021.
  • As of September 30, 2022, Rain had approximately 26.6 million shares of common stock outstanding.
  • The management of Rain Therapeutics will host a conference call and webcast for the investment community today, November 10, 2022 at 2:00 pm PT (5:00 pm ET).

Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

Retrieved on: 
星期五, 十一月 4, 2022
Private Securities Litigation Reform Act, Progression-free survival, RECIST, Therapy, LPS, Oncogene, CN, Histology, Food, PRS, Corporation, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, EGFR, FDA, Safety, KRAS, Neoplasm, CDKN2A, COVID-19, Genetics, RAD52, PIK3CA, MANTRA, Nasdaq, U.S. Securities and Exchange Commission, Clinical trial, Data, MDM2, Cancer, Health, Liposarcoma, Security (finance), RAIN, Bachelor of Medicine, Bachelor of Surgery, Patient, Biliary tract, Pharmaceutical industry, Medical imaging

NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead clinical candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced preliminary data in the multicenter, single arm, open-label, Phase 2 basket trial evaluating milademetan, an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of MDM2-amplified advanced solid tumors.

Key Points: 
  • We are encouraged by the preliminary observations from the MANTRA-2 trial, said Avanish Vellanki, co-founder and chief executive officer of Rain.
  • In addition, anti-tumor activity was observed in patients with genetic co-alterations, and in tumors with MDM2 copy number above 8.
  • Hence, we plan to revise the protocol to include patients tested locally for MDM2 copy number of 8 and greater.
  • Rain has completed enrollment in a Phase 3 trial of milademetan (MANTRA) in patients with LPS, and is evaluating milademetan in a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2).

Rain Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

Retrieved on: 
星期四, 八月 4, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, IO, Association, Histology, American Association, Accounting, GLOBE, R, Population, Annual general meeting, Private Securities Litigation Reform Act, RAIN, Investment, Clinical trial, MANTRA, Security (finance), RAD52, MDM2, Patient, Therapy, COVID-19, Prognosis, International, Program, American Association for Cancer Research, Liposarcoma, ICI, Safety, G&A, AACR, Research, Nasdaq, Webcast, CDKN2A, Merkel-cell carcinoma, Genetics, LPS, Food, Health, Pharmaceutical industry

NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) --  Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today reported financial results for the second quarter and six months ended June 30, 2022, along with an update on the Company’s key developments, business operations and upcoming milestones.

Key Points: 
  • As of June 30, 2022, Rain had $105.7 million in cash, cash equivalents and short-term investments.
  • Rain anticipates that its quarter-end cash position will provide runway into mid-2024 and therefore believes the milademetan program is well-funded.
  • As of June 30, 2022, Rain had approximately 26.5 million shares of common stock outstanding.
  • The management of Rain Therapeutics will host a conference call and webcast for the investment community today, August 4, 2022 at 2:00 pm PT (5:00 pm ET).

Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

Retrieved on: 
星期四, 八月 4, 2022
Private Securities Litigation Reform Act, Orphan, Security (finance), Population, CDKN2A, Standard of care, Bachelor of Medicine, Bachelor of Surgery, Cancer, Patient, Food, Review, U.S. Securities and Exchange Commission, Progression-free survival, Safety, FDA, Trabectedin, Extremities, MANTRA, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, PFS, MDM2, Genetics, GLOBE, LPS, Histology, Liposarcoma, Merkel-cell carcinoma, RAIN, WD, Incidence, RAD52, ICI, Pharmaceutical industry, Medicine

NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53. The trial targeted an enrollment of 160 patients and completed enrollment five months ahead of schedule with 175 patients.

Key Points: 
  • The trial targeted an enrollment of 160 patients and completed enrollment five months ahead of schedule with 175 patients.
  • MANTRA is an event-driven trial with progression-free survival (PFS) as the primary endpoint, which will be analyzed upon reaching 105 events.
  • The MANTRA trial is powered to show a doubling of PFS versus the standard of care.
  • Milademetan is being evaluated in an ongoing Phase 3 clinical trial in patients with LPS (MANTRA), as well as a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2).

Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

Retrieved on: 
星期四, 八月 4, 2022
Private Securities Litigation Reform Act, Orphan, Security (finance), CDKN2A, Standard of care, Bachelor of Medicine, Bachelor of Surgery, Cancer, Patient, Food, Review, U.S. Securities and Exchange Commission, Progression-free survival, Safety, FDA, Trabectedin, Extremities, MANTRA, Nasdaq, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, PFS, MDM2, Genetics, GLOBE, Liposarcoma, LPS, Histology, Merkel-cell carcinoma, RAIN, WD, Incidence, RAD52, ICI, Pharmaceutical industry

NEWARK, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced completion of enrollment in its Phase 3 MANTRA randomized, global, registrational trial of its lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53. The trial targeted an enrollment of 160 patients and completed enrollment five months ahead of schedule with 175 patients.

Key Points: 
  • The trial targeted an enrollment of 160 patients and completed enrollment five months ahead of schedule with 175 patients.
  • MANTRA is an event-driven trial with progression-free survival (PFS) as the primary endpoint, which will be analyzed upon reaching 105 events.
  • With a cash runway into the second quarter of 2024, we view Rain and the milademetan clinical program to be well-funded."
  • Milademetan is being evaluated in an ongoing Phase 3 clinical trial in patients with LPS (MANTRA), as well as a Phase 2 tumor-agnostic basket trial in certain solid tumors (MANTRA-2).

Rain Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Progress

Retrieved on: 
星期三, 五月 4, 2022
MANTRA, MDM2, RAD52, U.S. Securities and Exchange Commission, Investment, Private Securities Litigation Reform Act, GLOBE, Liposarcoma, Accounting, Company, Nasdaq, ICI, Safety, Food, Research, Patient, Histology, Security (finance), Webcast, FDA, International, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, LPS, CDKN2A, R, RAIN, Genetics, Merkel-cell carcinoma, G&A, Cancer, Fine chemical, Pharmaceutical industry

Rain continues to make strong progress in its ongoing milademetan trials, with topline data from the Phase 3 MANTRA liposarcoma trial now anticipated in the first half of 2023.

Key Points: 
  • Rain continues to make strong progress in its ongoing milademetan trials, with topline data from the Phase 3 MANTRA liposarcoma trial now anticipated in the first half of 2023.
  • As of March 31, 2022, Rain had $123.2 million in cash, cash equivalents and short-term investments.
  • As of March 31, 2022, Rain had approximately 26.5 million shares of common stock outstanding.
  • The management of Rain Therapeutics will host a conference call and webcast for the investment community today, May 4, 2022 at 2:00 pm PT (5:00 pm ET).

Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Progress

Retrieved on: 
星期四, 三月 3, 2022
Private Securities Litigation Reform Act, CDKN2A, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Therapy, Patient, Investment, G&A, PD-L1, MCC, RAD52, Genetics, Accounting, ICI, Food, Security (finance), Safety, U.S. Securities and Exchange Commission, Roche, Liposarcoma, FDA, Webcast, Orphan, Company, Cancer, RAIN, Phase 3, LPS, Histology, Merkel-cell carcinoma, MDM2, GLOBE, Nasdaq, Pharmaceutical industry, Fine chemical

NEWARK, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage company developing precision oncology therapeutics, today reports financial results for the fourth quarter and full year ended December 31, 2021, along with an update on the Company's key developments, business operations and upcoming milestones.

Key Points: 
  • Rain has achieved a number of important clinical milestones for milademetan including commencing two of the four planned trials in MDM2-dependent cancers.
  • Global site activations exceeded the target for year-end 2021, and all sites anticipated to be activated by the end of the first quarter of 2022.
  • Rain dosed the first patient in its multicenter, open-label Phase 2 basket trial (MANTRA-2) in November 2021, evaluating milademetan in MDM2-amplified advanced solid tumors.
  • Rain made significant progress in site activations for MANTRA-2 and anticipates all sites will be activated by the end of the first quarter of 2022.